Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;24(11):3985-3991.
doi: 10.31557/APJCP.2023.24.11.3985.

Toxicity of Carboplatin-Niosomal Nanoparticles in a Brain Cancer Cell Line

Mohadeseh Abbasi  1 , Reza Reihanisaransari  2 , Fatemeh Poustchi  3 , Ali Hheidari  4 , Parizad Ghanbarikondori  5 , Hanifeh Salehi  6 , Vahid Salehi  6 , Mohaddeseh Izadkhah  6 , Farimah Moazzam  7 , Mohammadreza Allahyartorkaman  8
Affiliations

Toxicity of Carboplatin-Niosomal Nanoparticles in a Brain Cancer Cell Line

Mohadeseh Abbasi et al. Asian Pac J Cancer Prev. .

Abstract

Objective: Cancer poses a significant challenge in modern medicine, standing as the primary cause of death in many countries, second only to cardiovascular diseases. Among the various treatments available, carboplatin, a chemotherapy drug, is employed for specific cancer types, including brain carcinoma. The main objective of this investigation is to enhance the therapeutic efficacy of carboplatin by utilizing niosomal nanocarriers.

Methods: We synthesized nanoniosomal carboplatin using the reverse-phase evaporation technique and conducted an assessment of its particle size, zeta potential, and drug-release properties. Subsequently, we evaluated the cytotoxicity of nanoniosomal carboplatin using the C6 rat glioma cell line.

Results: Our research revealed that these niosomal nanoparticles possessed a particle size of 290.5±5.5 nm and a zeta potential of -21.7±7.4 mV. The amount of encapsulated drug and drug loading level were found to be 60.2±2.3% and 2.5±1.1%, respectively. Importantly, the cytotoxic impact of these nanoniosomes on the C6 rat glioma cell line exhibited a significant increase compared to the free drug (P<0.05).

Conclusion: Based on our discoveries, it is evident that carboplatin niosomal nanocarriers hold potential as an innovative approach to chemotherapy for brain cancer therapy.

Keywords: Brain cancer; Carboplatin; Nanoniosome; Nanoparticle.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Figures

Figure 1
Figure 1
The Mean Size of Nanoniosomal Carboplatin
Figure 2
Figure 2
A Standard Carboplatin Curve was Generated by Measuring the Absorbance (optical density; OD) of Various Dilutions of Carboplatin Concentrations
Figure 3
Figure 3
The Graph Illustrates How Carboplatin is Released in Vitro from the Carboplatin Nanoniosomes into a PBS Buffer. The information is depicted as the mean value along with the standard deviation (SD), and it originates from three distinct experiments, with each experiment conducted twice
Figure 4.
Figure 4.
Viability Effects of Carboplatin-loaded Nanoparticles Compared to the Standard Drug (carboplatin) on C6 Rat Glioma Cell Line after 48-h Incubation. (Graph represents mean ± SD; n= 3 independent experiments, ***p = 0.0002, two-way ANOVA with Šidák test)
See this image and copyright information in PMC

References

    1. Ahmadi MS, Sheida F, Ameri A, et al. Ewing’s Sarcoma of Mandible: Practical Approach to a Challenging Case. Case Rep Oncol. 2022;15:927–35. - PMC - PubMed
    1. Ahmadi S, Seraj M, Chiani M, et al. In vitro development of controlled-release nanoniosomes for improved delivery and anticancer activity of letrozole for breast cancer treatment. Int J Nanomedicine. 2022:6233–55. - PMC - PubMed
    1. Alavi SE, Raza A, Esfahani MKM, et al. Carboplatin niosomal nanoplatform for potentiated chemotherapy. J Pharm Sci. 2022;111:3029–37. - PubMed
    1. Alimirzaei F, Kieslich CA. Computer Aided Chemical Engineering . Vol. 52. Elsevier; 2023. Machine learning models for predicting membranolytic anticancer peptides; pp. 2691–6.
    1. Allahyartorkaman M, Mirsaeidi M, Hamzehloo G, et al. Low diagnostic accuracy of Xpert MTB/RIF assay for extrapulmonary tuberculosis: A multicenter surveillance. Sci Rep. 2019;9:18515. - PMC - PubMed